Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
In this study patients with moderate to severe chronic graft-versus-host disease will be
treated with a combination of prednisone and everolimus. Patients will be treated on the
study for a maximum of 12 months and followed up for another 12 months.
The primary hypothesis of this study is that the addition of everolimus to prednisone
increases response rates without increasing treatment related mortality or mortality due to
relapse of underlying disease.